Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Aging

Volumn 8, Issue 8, 2016, Pages 1593-1607

  Fiorillo, Marco ^a,b,c   Lamb, Rebecca ^a,b   Tanowitz, Herbert B ^d   Cappello, Anna Rita ^c   Martinez Outschoorn, Ubaldo E ^e   Sotgia, Federica ^f   Lisanti, Michael P ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CALABRIA   (Italy)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Bedaquiline; Cancer stem like cells (CSCs); Drug repurposing; Mitochondria; Tumor initiating cells (TICs)

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; FIBROBLAST; HUMAN; MCF-7 CELL LINE; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; OXYGEN CONSUMPTION;

ANTITUBERCULAR AGENTS; CELL PROLIFERATION; CELL SURVIVAL; DIARYLQUINOLINES; FIBROBLASTS; HUMANS; MCF-7 CELLS; MITOCHONDRIA; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; OXYGEN CONSUMPTION;

EID: 84987858744     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100983     Document Type: Article

References (23)

1. Zhang M and Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2006; 16:60-64.
2. Fillmore CM and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that selfrenew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10:25.
3. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100:672-679.
4. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y and Tan W. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. J Pharmacol Sci. 2013; 122:299-304.
5. Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M and Barsky SH. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen. 2010; 15:820-829.
6. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012; 17:111-117.
7. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP and Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5:11029-11037. doi: 10.18632/oncotarget.2789.
8. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015; 6: 4569-84. doi: 10.18632/oncotarget.3174.
9. De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, Martinez-Outschoorn UE, Cappello AR, Pezzi V, Lisanti MP and Sotgia F. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget. 2015; 14777-95. doi: 10.18632/oncotarget.4401.
10. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K, Campos-Olivas R, Grana O, Viera CR, Yuneva M, Sainz B, Jr. and Heeschen C. MYC/PGC-1alpha Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab. 2015; 22:590-605.
11. Manago A, Leanza L, Carraretto L, Sassi N, Grancara S, Quintana-Cabrera R, Trimarco V, Toninello A, Scorrano L, Trentin L, Semenzato G, Gulbins E, Zoratti M and Szabo I. Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death Dis. 2015; 6:1930.
12. Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, Olsson H, Jernstrom H, Ek S, Gustavsson E, Ingvar C, Ohlsson M, Peterson C and Borrebaeck CA. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:14252-14257.
13. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005; 307:223-227.
14. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371:723-732.
15. Preiss L, Langer JD, Yildiz O, Eckhardt-Strelau L, Guillemont JE, Koul A and Meier T. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv. 2015; 1:1500106.
16. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A and Bald D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009; 53:1290-1292.
17. de Jonge MR, Koymans LH, Guillemont JE, Koul A and Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. 2007; 67:971-980.
18. Zheng J and Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol. 2000; 130:1115-1123.
19. Xia EQ, Deng GF, Guo YJ and Li HB. Biological activities of polyphenols from grapes. Int J Mol Sci. 2010; 11:622-646.
20. Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, Clarke RB, Howell SJ, Cappello AR, Martinez-Outschoorn UE, Peiris-Pages M, Sotgia F and Lisanti MP. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. Oncotarget. 2015; 6:14005-25. doi: 10.18632/oncotarget.4159.
21. Peiris-Pages M, Sotgia F and Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine hedgehog-GLI signaling in breast cancer cells. Oncotarget. 2015; 6: 10728-45. doi: 10.18632/oncotarget.3828.
22. Fiorillo M, Verre AF, Iliut M, Peiris-Pages M, Ozsvari B, Gandara R, Cappello AR, Sotgia F, Vijayaraghavan A and Lisanti MP. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". Oncotarget. 2015; 6:3553-62. doi: 10.18632/oncotarget.3348.
23. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast cancer research and treatment. 2010; 123:725-731.